CN1399562A - 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物 - Google Patents

基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物 Download PDF

Info

Publication number
CN1399562A
CN1399562A CN00816224A CN00816224A CN1399562A CN 1399562 A CN1399562 A CN 1399562A CN 00816224 A CN00816224 A CN 00816224A CN 00816224 A CN00816224 A CN 00816224A CN 1399562 A CN1399562 A CN 1399562A
Authority
CN
China
Prior art keywords
individual
antibody
polynucleotide
affinity
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00816224A
Other languages
English (en)
Chinese (zh)
Inventor
M·D·林尼克
P·A·麦克尼利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Pharmaceutical Co filed Critical La Jolla Pharmaceutical Co
Publication of CN1399562A publication Critical patent/CN1399562A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN00816224A 1999-11-28 2000-11-28 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物 Pending CN1399562A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16771699P 1999-11-28 1999-11-28
US60/167,716 1999-11-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008101656741A Division CN101422614A (zh) 1999-11-28 2000-11-28 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物

Publications (1)

Publication Number Publication Date
CN1399562A true CN1399562A (zh) 2003-02-26

Family

ID=22608518

Family Applications (2)

Application Number Title Priority Date Filing Date
CN00816224A Pending CN1399562A (zh) 1999-11-28 2000-11-28 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
CNA2008101656741A Pending CN101422614A (zh) 1999-11-28 2000-11-28 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2008101656741A Pending CN101422614A (zh) 1999-11-28 2000-11-28 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物

Country Status (11)

Country Link
US (2) US7081242B1 (https=)
EP (1) EP1233791A2 (https=)
JP (1) JP2003516526A (https=)
KR (1) KR20020059808A (https=)
CN (2) CN1399562A (https=)
AU (1) AU783282C (https=)
CA (1) CA2391944A1 (https=)
HK (1) HK1045944A1 (https=)
MX (1) MXPA02005236A (https=)
NO (1) NO20022441L (https=)
WO (1) WO2001041813A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102477079A (zh) * 2010-11-24 2012-05-30 中国人民解放军军事医学科学院基础医学研究所 一种新型多肽在系统性红斑狼疮诊断中的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
HK1045944A1 (zh) 1999-11-28 2002-12-20 La Jolla Pharmaceutical Company 基於抗体亲和力的狼疮治疗方法和筛选方法及用於其的组合物
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
AU2003303524A1 (en) * 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
US20040258683A1 (en) * 2003-03-30 2004-12-23 Linnik Matthew D. Methods of treating and monitoring systemic lupus erythematosus in individuals
US20060229270A1 (en) * 2005-03-10 2006-10-12 La Jolla Pharmaceutical Company Methods of treating proteinuria by reducing double-stranded DNA antibodies
WO2009052415A1 (en) * 2007-10-17 2009-04-23 The Regents Of The University Of California Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus
WO2012116210A2 (en) * 2011-02-23 2012-08-30 The Regents Of The University Of California Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126131A (en) 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5370871A (en) 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5162515A (en) 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
US5391785A (en) 1990-01-16 1995-02-21 La Jolla Pharmaceutial Company Intermediates for providing functional groups on the 5' end of oligonucleotides
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
AU8869291A (en) 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
IE922292A1 (en) 1991-07-15 1993-01-27 Jolla Pharma Modified phosphorous intermediates for providing functional¹groups on the 5' end of oligonucleotides
EP1808183A3 (en) 1993-09-08 2009-07-01 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
CA2183535A1 (en) 1994-02-28 1995-08-31 Ronald P. Taylor Antigen-based heteropolymers and method for treating autoimmune diseases using the same
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5856464A (en) 1995-06-07 1999-01-05 Lajolla Pharmaceutical Company Selective capping solution phase oligonucleotide synthesis
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
KR20000016414A (ko) 1996-06-06 2000-03-25 와이즈먼 앤드루 Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법
WO1998046523A1 (en) 1997-04-11 1998-10-22 Chiyoda Corporation Catalyst for preparation of synthesis gas and process for preparing carbon monoxide
EP1965213A3 (en) 1998-02-04 2009-07-15 Invitrogen Corporation Microarrays and uses therefor
DK1411075T3 (da) 1998-03-12 2008-10-27 Nektar Therapeutics Al Corp Fremgangsmåde til fremstilling af polymerkonjugater
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
MXPA01002580A (es) 1998-09-10 2002-04-08 Univ Virginia Anticuerpos para c3b(1) para el suministro de agentes de diagnostico y terapeuticos para celulas cancerosas.
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
JP2002531531A (ja) 1998-12-09 2002-09-24 ラ ホヤ ファーマシューティカル カンパニー 循環している抗体を減少させるための方法および処方物
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US20010010818A1 (en) 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
KR20020022691A (ko) 1999-06-08 2002-03-27 와이즈먼 앤드루 아미노옥시기를 포함하는 원자가 플랫폼 분자
HK1045944A1 (zh) 1999-11-28 2002-12-20 La Jolla Pharmaceutical Company 基於抗体亲和力的狼疮治疗方法和筛选方法及用於其的组合物
AU2593901A (en) 1999-12-23 2001-07-03 Elusys Therapeutics, Inc. Therapeutic use of particles displaying pathogen-specific binding moieties
EP1284752A4 (en) 2000-04-26 2004-08-18 Elusys Therapeutics Inc BISPECIFIC MOLECULES AND USES THEREOF
CN1434726A (zh) 2000-06-08 2003-08-06 拉卓拉药物公司 包含高分子量聚环氧乙烷的多价平台分子
AU4155602A (en) 2000-11-01 2002-06-18 Elusys Therapeutics Inc Method of producing biospecific molecules by protein trans-splicing
JP2004529945A (ja) 2001-05-17 2004-09-30 ラ ホヤ ファーマシューティカル カンパニー Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法
US20030114405A1 (en) 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
AU2003303524A1 (en) 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
US20040258683A1 (en) 2003-03-30 2004-12-23 Linnik Matthew D. Methods of treating and monitoring systemic lupus erythematosus in individuals

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102477079A (zh) * 2010-11-24 2012-05-30 中国人民解放军军事医学科学院基础医学研究所 一种新型多肽在系统性红斑狼疮诊断中的应用

Also Published As

Publication number Publication date
WO2001041813A3 (en) 2002-01-03
CA2391944A1 (en) 2001-06-14
JP2003516526A (ja) 2003-05-13
US20060142229A1 (en) 2006-06-29
AU3970201A (en) 2001-06-18
KR20020059808A (ko) 2002-07-13
US7081242B1 (en) 2006-07-25
CN101422614A (zh) 2009-05-06
MXPA02005236A (es) 2004-03-19
EP1233791A2 (en) 2002-08-28
NO20022441D0 (no) 2002-05-23
WO2001041813A2 (en) 2001-06-14
HK1045944A1 (zh) 2002-12-20
AU783282B2 (en) 2005-10-06
AU783282C (en) 2006-04-06
NO20022441L (no) 2002-07-09

Similar Documents

Publication Publication Date Title
JP7125370B2 (ja) 自己免疫疾患の治療及び／又は診断におけるアプタマーの使用
US11013756B2 (en) Anti-IL-17 aptamer having improved retention in blood
CN102099471B (zh) 针对il-17的适配体及其用途
EP3546481A2 (en) Anti-interleukin 22 (il-22) antibody and uses thereof
US20100152281A1 (en) Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
JP2006514920A (ja) 抗原提示細胞の選択サブセットの同時ローディング／活性化によりｔ細胞のエフェクタープロファイルを発生させ制御するための方法及び組成物
US20070191297A1 (en) Methods of treating and monitoring systemic lupus erythematosus in individuals
CN1399562A (zh) 基于抗体亲和力来治疗狼疮的方法及使用这种方法的筛选方法和组合物
US20220411527A1 (en) Compositions and methods for transferrin receptor 1 targeting
WO2018236986A1 (en) Engineered t-cell receptors and methods of their use
JP6586669B2 (ja) オートタキシンに結合しオートタキシンの生理活性を阻害するアプタマー及びその利用
US20070218072A1 (en) Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
CA2355348A1 (en) Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
US20250049848A1 (en) Methods and compositions for altering a tumor microbiome
US20240254216A1 (en) Variant library-coupled immunogenicity mapping of monoclonal antibody therapeutics
CA2993652C (en) Targeted oligonucleotides
WO2015147290A1 (ja) オートタキシンに結合しオートタキシンの生理活性を阻害するアプタマー及びその利用
JP2023542389A (ja) 自己抗体で媒介される状態の予防又は治療のための化合物
HK1245882B (zh) 多发性硬化的基因表达标志和治疗
CA2957314A1 (en) Antagonistic anti-ox40l antibodies and methods of their use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication